4583 — Chiome Bioscience Share Price
0.000.00%
Last trade - 00:00- ¥10bn
- ¥8bn
- ¥781m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.24 | ||
| Price to Tang. Book | 5.24 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 12.89 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -52.1% | ||
| Return on Equity | -66.33% | ||
| Operating Margin | -131.81% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 480.85 | 712.93 | 630.82 | 682.46 | 780.81 | n/a | n/a | 11.77% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Chiome Bioscience Inc. is a company mainly engaged in the research and development of antibody drugs, and the provision of development support services. The Company operates in two business segments. The Drug Discovery segment is engaged in the research and development of specific antibodies based on new antigens and mechanisms and licensing to pharmaceutical companies. The Drug Discovery Support segment is engaged in development of lead antibodies for therapeutic drugs in collaborating with pharmaceutical companies in Japan and overseas.
Directors
- Shigeru Kobayashi PRE (63)
- Arihiko Hijohira EXO (38)
- Tetsuya Ishino EXO
- Yasuji Nakamura EXO
- Takayuki Oda EXO
- Ryuji Ohsawa EXO (38)
- Zaigen Bijodaira OTH (40)
- Akiyuki Furuya IND (72)
- Tsutomu Kawaguchi IND (72)
- Haruhisa Kubota IND (69)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- February 8th, 2005
- Public Since
- December 20th, 2011
- No. of Employees
- 51
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Tokyo Stock Exchange
- Shares in Issue
- 68,456,851
- Address
- 12F,Smtm Fdsn Nshi-shnjk Bldg. No.6, SHIBUYA-KU, 151-0071
- Web
- https://www.chiome.co.jp/
- Phone
- +81 363833561
- Auditors
- Deloitte Touche Tohmatsu LLC
Upcoming Events for 4583
Similar to 4583
3-D Matrix
Tokyo Stock Exchange
AnGes
Tokyo Stock Exchange
BrightPath Biotherapeutics Co
Tokyo Stock Exchange
Carna Biosciences
Tokyo Stock Exchange
Chordia Therapeutics
Tokyo Stock Exchange
FAQ
What is the Chiome Bioscience share price?
As of Today at 18:56 UTC, shares in Chiome Bioscience are trading at ¥147. This share price information is delayed by 15 minutes.
How has the Chiome Bioscience share price performed this year?
Shares in Chiome Bioscience last closed at ¥147 and the price had moved by +5% over the past 365 days. In terms of relative price strength the Chiome Bioscience share price has outperformed the Nikkei 225 Index by +12.83% over the past year.
What are the analyst and broker recommendations for Chiome Bioscience?
There is no consensus recommendation for this security.
Find out moreWhat is the Chiome Bioscience dividend yield?
Chiome Bioscience does not currently pay a dividend.
Does Chiome Bioscience pay a dividend?
Chiome Bioscience does not currently pay a dividend.
When does Chiome Bioscience next pay dividends?
Chiome Bioscience does not currently pay a dividend.
How do I buy Chiome Bioscience shares?
To buy shares in Chiome Bioscience you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Chiome Bioscience?
As of the previous close price of ¥147, shares in Chiome Bioscience had a market capitalisation of ¥10bn.
Where are Chiome Bioscience shares listed?
Here are the trading details for Chiome Bioscience:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4583
What kind of share is Chiome Bioscience?
Based on an overall assessment of its quality, value and momentum Chiome Bioscience is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Chiome Bioscience share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Chiome Bioscience share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Chiome Bioscience. Over the past six months, its share price has outperformed the Nikkei 225 Index by +29.84%.
As of the last closing price of ¥147, shares in Chiome Bioscience were trading -4.65% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Chiome Bioscience PE Ratio?
The Chiome Bioscience PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at ¥147.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Chiome Bioscience?
Chiome Bioscience's management team is headed by:
- Shigeru Kobayashi - PRE
- Arihiko Hijohira - EXO
- Tetsuya Ishino - EXO
- Yasuji Nakamura - EXO
- Takayuki Oda - EXO
- Ryuji Ohsawa - EXO
- Zaigen Bijodaira - OTH
- Akiyuki Furuya - IND
- Tsutomu Kawaguchi - IND
- Haruhisa Kubota - IND